Get started
Author

Maciej Gil

Futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC): Preliminary safety results from a phase 2 study.
2022 · Vadim S Koshkin, Guru P. Sonpavde, et al. · Journal of Clinical Oncology · 19
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with Stage IV non-small cell lung cancer
2020 · Benjamin Besse, Pilar Garrido, et al. · Lung Cancer · 19
Plasma fibrinogen and troponin I in acute coronary syndrome and stable angina
2002 · Maciej Gil, Maciej Zarȩbiński, et al. · International Journal of Cardiology · 19
1965MO Phase II study of futibatinib plus pembrolizumab in patients (pts) with advanced/metastatic urothelial carcinoma (mUC): Final analysis of efficacy and safety
2024 · V.S. Koshkin, P. Barthelemy, et al. · Annals of Oncology · 7
Abstract RF01-04: Final results from the phase 2, open-label FOENIX-MBC2 study: efficacy and safety of futibatinib in adult patients with locally advanced/metastatic HR+/HER2− breast cancer harboring high-level FGFR1 gene amplification
2024 · Senthil Damodaran, Fabrice André, et al. · Cancer Research · 5
MA09.11 Efficacy and Safety of Necitumumab and Pembrolizumab Combination Therapy in Stage IV Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
2017 · Benjamin Besse, Pilar Garrido, et al. · Journal of Thoracic Oncology · 5
A phase 2 study of LY3023414 and necitumumab after first-line chemotherapy for metastatic squamous non-small cell lung cancer (NSCLC)
2016 · M. Johnson, V. Wacheck, et al. · Annals of Oncology · 4
A phase 1, open-label, first-in-human study of TAS2940 in patients with advanced solid tumors.
2023 · Jordi Rodon Ahnert, David R. Spigel, et al. · Journal of Clinical Oncology · 3
Abstract P1-18-35: Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study
2022 · Senthil Damodaran, Nisha Unni, et al. · Cancer Research · 3
Severity of coronary artery disease in patients with acute coronary syndrome without ST segment elevation is related to baseline troponin I and ST-segment depression.
2003 · Maciej Gil, Maciej Zarebiński, et al. · PubMed · 3
Topical versus systemic 5-aminolevulinic acid administration for photodynamic therapy of the colon in B10.RBP mice
1999 · Maciej Gil, Marek Woszczynski, et al. · Journal of Biomedical Optics · 3
PDF
Abstract PO4-06-07: Efficacy and safety of futibatinib in patients with locally advanced/metastatic triple-negative breast cancer harboring FGFR2 gene amplification: final results from the phase 2, open-label FOENIX-MBC2 study
2024 · Antonio Giordano, Nisha Unni, et al. · Cancer Research · 1
Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non-Lenalidomide-Based Treatments in the Real-World MM-034 Study
2022 · Michele Cavo, Sujith Dhanasiri, et al. · Blood · 1
135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer
2018 · B. Besse, F. Barlesi, et al. · Journal of Thoracic Oncology · 1
PDF
P3.02b-062 Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC)
2017 · Benjamin Besse, Johan Vansteenkiste, et al. · Journal of Thoracic Oncology · 1
PDF
[Severity of coronary artery disease in patients with acute coronary syndrome without ST segment elevation].
2005 · Jerzy Adamus, Maciej Zarebiński, et al. · PubMed · 1
A phase 2 study of futibatinib plus pembrolizumab in patients (pts) with advanced or metastatic urothelial carcinoma (mUC)
2021 · G. Sonpavde, V.S. Koshkin, et al. · European Urology Open Science
Works count: 17
Citation count: 95
H-index: 5
I10-index: 3
Year
Topic
Type